It is in fact well documented that cancer cells tend to upregulate various complement receptors and membrane bound complement inhibitors, including CD59 but also CD46 and CD5510,31; interestingly, our study is the first, to our knowledge, demonstrating an up-regulation of CD59 in a tissue before the onset of the neoplastic disease. This evidence concerns the gene CD46 and cancer.